Why Aditxt Shares Dipped Over 58%; Here Are 82 Biggest Movers From Friday
Gainers
Panbela Therapeutics, Inc. (NASDAQ: PBLA) shares jumped 53% to close at $0.58 on Friday.
Why NCR Is Trading Lower By Around 23%, Here Are 42 Stocks Moving In Friday’s Mid-Day Session
Gainers
Kensington Capital Acquisition Corp. IV (NYSE: AMPX) jumped 35.4% to $13.54 after gaining 11% on Thursday.
Northland Capital Markets Maintains Outperform on Nabriva Therapeutics. Price Adjusts to $18.
Northland Capital Markets analyst Carl Byrnes maintains Nabriva Therapeutics (NASDAQ:NBRV) with a Outperform. Price Adjusts to $18
Why Adobe Is Trading Lower By 17%, Here Are 49 Stocks Moving In Thursday’s Mid-Day Session
Gainers
HeartBeam, Inc. (NASDAQ: BEAT) shares surged 58% to $1.96 after the company announced its patent for a 12-lead electrocardiogram patch monitor intended for detection of acute coronary syndrome and cardiac arrhythmia was issued by the USPTO.
Recap: Nabriva Therapeutics Q2 Earnings
Nabriva Therapeutics (NASDAQ:NBRV) reported its Q2 earnings results on Wednesday, August 3, 2022 at 04:00 PM.
Here's what investors need to know about the announcement.
Nabriva Therapeutics Q1 EPS $(0.20) Misses $(0.19) Estimate, Sales $8.00M Miss $9.57M Estimate
Nabriva Therapeutics (NASDAQ:NBRV) reported quarterly losses of $(0.20) per share which missed the analyst consensus estimate of $(0.19) by 5.26 percent. This is a 62.26 percent increase over losses of $(0.53) per share
Earnings Scheduled For May 5, 2022
Companies Reporting Before The Bell
• Mirum Pharmaceuticals (NASDAQ:MIRM) is expected to report quarterly loss at $1.34 per share on revenue of $8.46 million.
A Preview Of Nabriva Therapeutics’s Earnings
Nabriva Therapeutics (NASDAQ:NBRV) is set to give its latest quarterly earnings report on Thursday, 2022-05-05. Here's what investors need to know before the announcement.
Analysts estimate that Nabriva Therapeutics will report an earnings per share (EPS) of $-0.19.